Dragonfly Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing therapies that utilize its advanced multispecific antibody technology, with a specific focus on cancer immunotherapy. The company aims to harness the body's immune system to create breakthrough treatments, particularly through the invention of natural killer cell-based therapies that promise significantly improved outcomes for patients. Dragonfly Therapeutics is engaged in both clinical and preclinical research, boasting an extensive pipeline of assets and collaborations with major pharmaceutical partners such as Merck, AbbVie, Gilead, and Bristol Myers Squibb. With a mission to revolutionize disease treatment and a commitment to maintaining high ethical and scientific standards, Dragonfly Therapeutics promotes a collaborative and impactful work environment.